AstraZeneca to Fully Acquire Caelum Biosciences

AstraZeneca’s Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody (mAb) for the treatment of light chain (AL) amyloidosis. AL amyloidosis is a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys, causing significant organ damage and failure that may ultimately be fatal. In 2019 Caelum and Alexion first entered into a collaboration whereby Alexion acquired a minority equity interest and an exclusive option to acquire the remaining equity in Caelum.

ANP Technologies, Inc. Terminates Merger Negotiations with Sorrento Therapeutics, Inc.

ANP Technologies, Inc. (ANP) announced the termination of the binding acquisition Term Sheet with Sorrento Therapeutics, Inc. (SRNE), effective September 28, 2021. The effect of this termination now allows ANP to freely explore other business opportunities with parties interested in ANP’s diagnostic and platform drug delivery technologies. ANP Technologies, Inc. is a clinical stage biopharmaceutical company and a world leader in developing innovative nano-therapeutics and nano-diagnostic tests.

COVID Has Made Biotech Companies the Hot New Tech Sector as Investor Demand Drives Record IPOs

The ongoing Covid-19 pandemic has made biotech companies the hot new technology sector as investor demand drives record IPOs, a panel of top investors told CNBC on Wednesday. The biotech sector has drawn a lot of attention over the last two years during the pandemic, primarily because “we generated all the life-saving drugs, vaccines, and therapeutics that literally just saved the world,” Christiana Bardon, a portfolio manager at private equity firm MPM Capital, told CNBC’s Meg Tirrell at the “Delivering Alpha” conference.

Particle Dynamics Announces Sale to New Ownership Group Led by BroadOak Capital Partners

Particle Dynamics, a global leader in particle processing, delivery technologies, and finished dose manufacturing for pharmaceutical, over-the-counter (“OTC”), and nutraceutical companies, has sold from Edgewater Capital Partners to a new ownership group led by BroadOak Capital Partners (“BroadOak”). The new ownership group comprises BroadOak, Research Corporation Technologies (“RCT”), and Farragut Capital Partners (“Farragut”); BroadOak and Farragut provided subordinated debt to Particle Dynamics in 2019 as part of a recapitalization.

NovaBay Pharmaceuticals Signs Agreement to Acquire DERMAdoctor

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it has entered into a definitive agreement to acquire DERMAdoctor, LLC, a privately-held company that commercializes dermatologist-developed skincare products, including all of its inventory, products and intellectual property, for a purchase price of $15.0 million, comprised of $12.0 million in cash at closing and up to an additional $3 million in earnout payments contingent upon the DERMAdoctor business achieving predetermined financial targets for the 2022 and the 2023 fiscal years.

Merck Nears Deal to Acquire Acceleron Pharma

Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant’s rare-disease business. The deal for Acceleron, which has a market value of around $11 billion, could be announced this week, assuming talks don’t fall apart, the people said. Should a deal come together, it would be one of Merck’s biggest and represent a bet on the treatments for the respiratory and blood diseases that Acceleron specializes in.

Hikma Strengthens US Injectables Business through Acquisition of Custopharm from Water Street

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company and one of the largest suppliers of generic injectable medicines in the US, today announces that it has agreed to acquire Custopharm Inc. (‘Custopharm’) from Water Street Healthcare Partners (‘Water Street’). Hikma will pay an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in contingent consideration payable upon the achievement of certain commercial milestones. Custopharm, a US-based generic sterile injectables company with a differentiated product portfolio and R&D pipeline, currently markets its products in the US through its commercial arm Leucadia Pharmaceuticals.

Jasper Therapeutics Closes Transaction with Amplitude Healthcare Acquisition Corporation

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, announced Friday the completion of its business combination with Amplitude Healthcare Acquisition Corporation (Nasdaq:AMHC), a special purpose acquisition company sponsored by affiliates of Avego Management, LLC and Metalmark Capital. The business combination closed on September 24, 2021. Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell.

H.I.G. Capital Acquires Aspire Pharma

H.I.G. Capital, LLC (“H.I.G.”), a leading global alternative investment firm with $45 billion of equity capital under management, is pleased to announce that one of its affiliates has acquired Aspire Pharma Limited (“Aspire” or the “Company”), a leading UK provider of niche generic and branded specialty pharmaceuticals, alongside its founder Graham Fraser-Pye. Aspire licenses and develops niche generic and specialty pharmaceutical products that offer innovative formulations, value for money for payors, and reliable supply arrangements in markets that are often underserved. The business holds leadership positions in urology, ophthalmology, CNS and dermatology, with a highly diversified portfolio of more than 250 products across multiple categories.

Amplitude Healthcare Acquisition Corporation Announces Shareholder Approval of Business Combination with Jasper Therapeutics, Inc.

Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHC) (“AMHC”), a special purpose acquisition company, announced Wednesday that its stockholders voted to approve the previously announced business combination (the “Business Combination”) with Jasper Therapeutics, Inc. (“Jasper”), a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell, and all other proposals presented at AMHC’’s special shareholder’s meeting held on September 22, 2021.